CTX-471 is under clinical development by Compass Therapeutics and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I drugs for Metastatic Melanoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CTX-471’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CTX-471 is under development for the treatment of metastatic solid tumors including mucosal melanoma, metastatic melanoma, mesothelioma, non-small cell lung cancer, head and neck cancer and small-cell lung cancer. CTX-471 acts by targeting TNF superfamily and its ligands. It is administered by intravenous route. The drug candidate is developed based on StitchMabs and Sympleitope technologies. It acts by targeting CD137.
Compass Therapeutics overview
Compass Therapeutics is a biotechnology company. The company’s product pipeline includes CTX-471, CTX-009, CTX-8371 and others. It develops transformational therapies for cancer, inflammation and autoimmune diseases. The company is involved in the discovery of antibody-drug candidates with a focus on T cells, NK cells and macrophages. Compass Therapeutics develops both agonists and antagonists, which facilitate the development of monotherapies and combination therapies. It utilizes Sympleitope technology platform for epitope screening and selection; and StitchMabs, a novel multi specific antibody screening platform that combines monoclonal antibodies into various specific formats. Compass Therapeutics is headquartered in Boston, Massachusetts, the US.
For a complete picture of CTX-471’s drug-specific PTSR and LoA scores, buy the report here.